Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients (Q24245120)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

0 references

1 reference

title

Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Angela Webster

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Jonathan Craig

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

E M Hodson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

C A Jones

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

18 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

CD005129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3.

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Cytomegalovirus hyperimmunoglobulin prophylaxis following kidney transplantation. Results of a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

A Randomized Prospective Trial of Acyclovir and Immune Globulin Prophylaxis in Liver Transplant Recipients Receiving OKT3 Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Infection in organ-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Cytomegalovirus infection in heart transplant recipients: Preliminary results of a controlled trial of intravenous gamma globulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Effects of Interferon-Alpha on Cytomegalovirus Reactivation Syndromes in Renal-Transplant Recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Hyperimmune globulin prophylaxis for cytomegalovirus infection in renal transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

CMV prophylaxis in high-risk renal transplant patients (D+/R-) by acyclovir with or without hyperimmune (CMV) immunoglobulins: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005129.PUB2

7 January 2021

10.1002/14651858.CD005129.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17443573%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference